ICU Medical, Inc. (NASDAQ:ICUI) Receives Average Rating of “Moderate Buy” from Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has been given a consensus recommendation of “Moderate Buy” by the five analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $175.6667.

ICUI has been the topic of a number of recent research reports. Wall Street Zen cut shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. KeyCorp increased their price target on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Piper Sandler boosted their price objective on ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th.

ICU Medical Stock Performance

ICU Medical stock opened at $146.37 on Thursday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.45 and a quick ratio of 1.19. ICU Medical has a 12 month low of $107.00 and a 12 month high of $175.51. The company has a fifty day moving average price of $133.64 and a two-hundred day moving average price of $129.67. The company has a market cap of $3.61 billion, a PE ratio of -472.15 and a beta of 0.82.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.43 by $0.60. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The company had revenue of $533.30 million for the quarter, compared to the consensus estimate of $511.46 million. During the same period last year, the firm posted $1.59 EPS. The company’s revenue for the quarter was down 8.9% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. Research analysts expect that ICU Medical will post 4.11 earnings per share for the current year.

Insider Buying and Selling at ICU Medical

In other news, Director Elisha W. Finney sold 1,285 shares of the company’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total transaction of $180,439.70. Following the completion of the transaction, the director owned 3,995 shares in the company, valued at approximately $560,977.90. This represents a 24.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Virginia Ruth Sanzone sold 930 shares of ICU Medical stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total transaction of $132,376.20. Following the completion of the sale, the vice president owned 5,456 shares in the company, valued at approximately $776,607.04. This represents a 14.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Several hedge funds and other institutional investors have recently made changes to their positions in ICUI. Cullen Frost Bankers Inc. acquired a new position in ICU Medical during the 2nd quarter worth $38,000. SJS Investment Consulting Inc. increased its holdings in shares of ICU Medical by 41,000.0% during the third quarter. SJS Investment Consulting Inc. now owns 411 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 410 shares during the period. Covestor Ltd raised its stake in shares of ICU Medical by 70.7% during the third quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock valued at $68,000 after purchasing an additional 236 shares in the last quarter. Blue Trust Inc. lifted its holdings in ICU Medical by 17.6% in the second quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock worth $124,000 after purchasing an additional 141 shares during the period. Finally, Smartleaf Asset Management LLC lifted its holdings in ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares during the period. 96.10% of the stock is currently owned by institutional investors and hedge funds.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.